Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Invesco NASDAQ 100 ETF (QQQM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Invesco NASDAQ 100 ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Invesco NASDAQ 100 ETF trades at $292.69. Which is the better fit depends on your goals.
| ACAD | QQQM | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $28.06 | $307.23 |
52-Week Low | $20.06 | $227.35 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
QQQM trades at $297.52, up 1.4% with bullish technical signals from moving averages. The ETF benefits from SpaceX's imminent Nasdaq-100 inclusion on July 7, 2026, expected to bring modest 1% weighting. Technical analysis shows support at $296 and resistance at $299, with overall bullish momentum supported by 12 buy signals versus 4 sell signals.
The outlook remains positive with AI-driven growth exposure and new index additions. Risks include concentration in large-cap tech and market volatility. Analyst sentiment favors long-term holding given the ETF's cost efficiency and growth potential in technology sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Invesco NASDAQ 100 ETF
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →
